Oxford BioDynamics (LON:OBD) Sets New 52-Week Low – Should You Sell?

Oxford BioDynamics Plc (LON:OBD) hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as GBX 0.23 and last traded at GBX 0.24, with a volume of 57837910 shares changing hands. The stock had previously closed at GBX 0.25.

Analyst Upgrades and Downgrades

Separately, Shore Capital reiterated a “house stock” rating on shares of Oxford BioDynamics in a report on Wednesday, October 8th.

Oxford BioDynamics Trading Down 0.8%

The company has a market capitalization of £10.21 million, a price-to-earnings ratio of -0.08 and a beta of 0.42. The company has a quick ratio of 2.80, a current ratio of 0.68 and a debt-to-equity ratio of 370.22. The company’s 50 day simple moving average is GBX 0.32 and its two-hundred day simple moving average is GBX 0.40.

Oxford BioDynamics Company Profile

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.